Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Share-based Compensation (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Share-based Compensation for 12 consecutive years, with $232000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 29.05% year-over-year to $232000.0, compared with a TTM value of $1.6 million through Sep 2025, up 9.73%, and an annual FY2024 reading of $1.7 million, down 18.89% over the prior year.
  • Share-based Compensation was $232000.0 for Q3 2025 at Lisata Therapeutics, down from $239000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $675000.0 in Q1 2023 and bottomed at $232000.0 in Q3 2025.
  • Average Share-based Compensation over 3 years is $426545.5, with a median of $454000.0 recorded in 2024.
  • Peak annual rise in Share-based Compensation hit 34.25% in 2024, while the deepest fall reached 59.35% in 2024.
  • Year by year, Share-based Compensation stood at $473000.0 in 2023, then soared by 34.25% to $635000.0 in 2024, then tumbled by 63.46% to $232000.0 in 2025.
  • Business Quant data shows Share-based Compensation for LSTA at $232000.0 in Q3 2025, $239000.0 in Q2 2025, and $530000.0 in Q1 2025.